HbA1c as a Predictor of Diabetes and as an Outcome in the Diabetes Prevention Program: A Randomized Clinical Trial

Abstract

OBJECTIVEGlycated hemoglobin (HbA1c), a standard measure of chronic glycemia for managing diabetes, has been proposed to diagnose diabetes and identify people at risk. The Diabetes Prevention Program (DPP) was a 3.2-year randomized clinical trial of preventing type 2 diabetes with a 10-year follow-up study, the DPP Outcomes Study (DPPOS). We evaluated baseline HbA1c as a predictor of diabetes and determined the effects of treatments on diabetes defined by an HbA1c ≥6.5% (48 mmol/mol).RESEARCH DESIGN AND METHODSWe randomized 3,234 nondiabetic adults at high risk of diabetes to placebo, metformin, or intensive lifestyle intervention and followed them for the development of diabetes as diagnosed by fasting plasma glucose (FPG) and 2-h postload glucose (2hPG) concentrations (1997 American Diabetes Association [ADA] criteria). HbA1c was measured but not used for study eligibility or outcomes. We now evaluate treatment effects in the 2,765 participants who did not have diabetes at baseline according to FPG, 2hPG, or HbA1c (2010 ADA criteria).RESULTSBaseline HbA1c predicted incident diabetes in all treatment groups. Diabetes incidence defined by HbA1c ≥6.5% was reduced by 44% by metformin and 49% by lifestyle during the DPP and by 38% by metformin and 29% by lifestyle throughout follow-up. Unlike the primary DPP and DPPOS findings based on glucose criteria, metformin and lifestyle were similarly effective in preventing diabetes defined by HbA1c.CONCLUSIONSHbA1c predicted incident diabetes. In contrast to the superiority of the lifestyle intervention on glucose-defined diabetes, metformin and lifestyle interventions had similar effects in preventing HbA1c-defined diabetes. The long-term implications for other health outcomes remain to be determined.

Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study

“…Thus, a secondary analysis using HbA 1c ≥ 6.5% (≥ 48 mmol/mol) as an alternative definition of diabetes was performed, excluding the 13 % of participants with HbA 1c ≥6.5 % (≥48 mmol/mol) at study entry. Although ILS was more effective than metformin in reducing the incidence of diabetes defined by the FPG and OGTT criteria, the effect of metformin was no longer significantly different from ILS when diabetes was diagnosed based on HbA 1c (44 % vs 49 % reduction in the DPP, 38 % vs 29 % reduction throughout DPP/DPPOS; metformin vs ILS) [23]. In summary, metformin was as effective as ILS in preventing diabetes by some measures (i.e.…”

Prognostic value of Diabetes in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy

“…A longer follow-up time may be needed in future studies addressing the prognostic value of diabetes. Glycated haemoglobin (HbA1c) was recently reported to be a more reliable marker diabetes management 29 , and this could be incorporated into any future research.…”

Metformin as a Tool to Target Aging

“…Over 3,000 subjects were randomly assigned to placebo, metformin (850 mg twice daily), or a lifestyle-modification program. Metformin reduced the incidence of T2DM by 31% compared to placebo over a mean follow-up of ~3 years and was effective in all age categories in preventing diabetes, defined by HbA1C level, including the ~20% who were age 60 or older at baseline (Knowler et al, 2015). Further, metformin treatment was associated with improvement in cardiovascular disease (CVD) risk factors (Goldberg et al, 2013; Haffner et al, 2005) and subclinical atherosclerosis (coronary artery calcium) in male participants (Goldberg et al, 2015).…”